The case of remdesivir illustrates that various hurdles in licensing, manufacturing, and distribution must be overcome to ensure adequate and equitable access to treatments, vaccines, diagnostics, and other medical equipment for COVID-19. There is a growing consensus among political leaders and civil society that COVID-19 medical products are global public goods and must be made available to all globally who need them. No country is safe from COVID-19 until all are safe.